Anticoagulants currently used in clinical practice to treat thromboembolic disorders are effective but increase the risk of severe bleeding because they target proteins that are essential for normal coagulation (hemostasis). Drugs with better safety profiles are required for prevention and treatment of thromboembolic disease. Coagulation factor XIa has emerged as a novel target for safer anticoagulant therapy because of its role in thrombosis and its relatively small contribution to hemostasis.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4167190 | PMC |
| http://dx.doi.org/10.1016/j.drudis.2014.05.018 | DOI Listing |
Publication Analysis
Top Keywords
factor target
4
target antithrombotic
4
antithrombotic therapy
4
therapy anticoagulants
4
anticoagulants currently
4
currently clinical
4
clinical practice
4
practice treat
4
treat thromboembolic
4
thromboembolic disorders
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!